Johnson & Johnson (JNJ)vsNutex Health Inc (NUTX)
JNJ
Johnson & Johnson
$232.77
+1.07%
HEALTHCARE · Cap: $536.54B
NUTX
Nutex Health Inc
$135.10
+1.71%
HEALTHCARE · Cap: $927.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10851% more annual revenue ($96.36B vs $879.95M). JNJ leads profitability with a 21.8% profit margin vs 11.0%. NUTX trades at a lower P/E of 9.9x. NUTX earns a higher WallStSmart Score of 64/100 (C+).
JNJ
Buy59
out of 100
Grade: C
NUTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Margin of Safety
+63.6%
Fair Value
$283.22
Current Price
$135.10
$148.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 37.5%
Earnings expanding 95.9% YoY
Every $100 of equity generates 28 in profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
2.2% revenue growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NUTX
The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NUTX
The primary concerns for NUTX are Revenue Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NUTX is a value play — different risk/reward profiles.
NUTX carries more volatility with a beta of 2.06 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
NUTX scores higher overall (64/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nutex Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?